He said the law has helped businesses and allows the nation to be competitive.
Nevada's next attorney general Aaron (AY'-ron) Ford says finding a way to implement a stalled, voter-approved gun background check law is one of the top issues the Democrat will tackle when he takes office early next year.
ObamaCare sign-ups have significantly declined so far in 2018.
The ruling was tied to a provision removed under Trump’s tax overhaul.
Stocks are sagging Friday after weak economic data from China has investors worrying about the global economy again.
The Dow member is taking a hit from investors.
Antelliq Group makes digital identification products for animals.
The Nasdaq turned negative for the week, joining the Dow and S&P 500.
New York state is suing two of the nation's largest retailers and a third company for importing and selling children's toys with lead levels up to 10 times higher than federal limits.
Toyota is recalling nearly 143,000 SUVs and pickups worldwide to fix air bag and brake problems.
The eye screening program in Thailand follows a similar Google program in India.
Toyota is recalling about 70,000 Toyota and Lexus brand vehicles in North America to replace air bag inflators that could explode and hurl shrapnel at drivers and passengers.
Christopher Clough has pleaded not guilty to receiving kickbacks.
However, J&J said Tremfya was not superior to Cosentyx in demonstrating quicker effectiveness.
MedMen CEO and Co-Founder Adam Bierman discusses the industry's greatest hurdles and why mainstreaming marijuana is the mission behind the cannabis dispensary company.
Monika Krcova did not want to follow the official guidelines and remain in the Slovakian hospital for four days after her third baby's birth.
Generic drugs account for the majority of prescriptions filled in the U.S.
Fox News medical correspondent Dr. Marc Siegel on Australian researchers developing a new 10-minute screening to test for cancer in the body.
The industry veteran will be tasked with helping the drug company revive sales, recover from a disappointing deal.
A generic drugmaker plans to start selling a slightly cheaper version of the EpiPen in the U.S. early next year.